NSAIDs Inhibit Tumorigenesis, but How?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-12-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-13-1573PMID 24311630PMCID PMC3947450
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Novel Sulindac Derivative Inhibits Lung Adenocarcinoma Cell Growth through Suppression of Akt/mTOR Signaling and Induction of Autophagy

  2013cited by this paper
• Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling

  2013cited by this paper
• Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: Relevant similarities to and important differences from celecoxib

  2013cited by this paper
• Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis

  2013cited by this paper
• COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs

  2013cited by this paper
• Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.

  2012cited by this paper
• Sulindac inhibits tumor cell invasion by suppressing NF-κB mediated transcription of microRNAs

  2012cited by this paper
• The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase

  2012cited by this paper
• A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and β-Catenin Transcriptional Activity

  2012cited by this paper
• Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/β-Catenin–Mediated Transcription in Human Breast Tumor Cells

  2011cited by this paper
• COX inhibitors directly alter gene expression: role in cancer prevention?

  2011cited by this paper
• Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

  2011cited by this paper
• Non-Steroidal Anti-Inflammatory Drugs and Colorectal Cancer Risk in a Large, Prospective Cohort

  2011cited by this paper
• The Role of NAG-1/GDF15 in the Inhibition of Intestinal Polyps in APC/Min Mice by Sulindac

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Sulindac Sulfide Reverses Aberrant Self-Renewal of Progenitor Cells Induced by the AML-Associated Fusion Proteins PML/RARα and PLZF/RARα

  2011cited by this paper
• PKG inhibits TCF signaling in colon cancer cells by blocking β-catenin expression and activating FOXO4

  2010cited by this paper
• Aspirin intake and survival after breast cancer.

  2010cited by this paper
• Colon Tumor Cell Growth–Inhibitory Activity of Sulindac Sulfide and Other Nonsteroidal Anti-Inflammatory Drugs Is Associated with Phosphodiesterase 5 Inhibition

  2010cited by this paper
• NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

  2010cited by this paper
• A Novel Sulindac Derivative Lacking Cyclooxygenase-Inhibitory Activities Suppresses Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate Model

  2010cited by this paper
• Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis

  2010cited by this paper
• Chemopreventive Efficacy of Naproxen and Nitric Oxide–naproxen in Rodent Models of Colon, Urinary Bladder, and Mammary Cancers

  2009cited by this paper
• Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G

  2009cited by this paper
• Aspirin use and survival after diagnosis of colorectal cancer.

  2009cited by this paper
• A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity

  2009cited by this paper
• Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis

  2008cited by this paper
• Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

  2008cited by this paper
• Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.

  2007cited by this paper
• Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib

  2007cited by this paper
• Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence

  2007cited by this paper
• NSAID activated gene (NAG-1), a modulator of tumorigenesis.

  2006cited by this paper
• Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas

  2006cited by this paper
• Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment.

  2006cited by this paper
• Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.

  2006cited by this paper
• Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.

  2006cited by this paper
• Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study

  2005cited by this paper
• The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis.

  2005cited by this paper
• Involvement of Intracellular Ca2+ Levels in Nonsteroidal Anti-inflammatory Drug-induced Apoptosis*

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Sulindac and its metabolites inhibit invasion of glioblastoma cells via down‐regulation of Akt/PKB and MMP‐2

  2005cited by this paper
• Targeting the beta‐catenin/APC pathway: a novel mechanism to explain the cyclooxygenase‐2‐independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

  2005cited by this paper
• Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2

  2005cited by this paper
• Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.

  2004cited by this paper
• From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors

  2004cited by this paper
• Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines

  2004cited by this paper
• Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity

  2004cited by this paper
• Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms.

  2004cited by this paper
• μ-Calpain Activation in β-Lapachone-Mediated Apoptosis

  2003cited by this paper
• Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells.

  2003cited by this paper
• Chemopreventive Strategies Using NSAIDs and COX-2 Inhibitors

  2003cited by this paper
• Anti-Angiogenic and Apoptotic Effects of Metabolites of Sulindac on Chick Embryo Chorioallantoic Membrane

  2003cited by this paper
• Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs

  2003cited by this paper
• Colon cancer prevention by NSAIDs: what is the mechanism of action?

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.

  2002cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ Is a Target of Nonsteroidal Anti-Inflammatory Drugs Mediating Cyclooxygenase-Independent Inhibition of Lung Cancer Cell Growth

  2002cited by this paper
• Wnt/Beta-Catenin/Tcf Signaling: A Critical Pathway in Gastrointestinal Tumorigenesis

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth.

  2002cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation

  2001cited by this paper
• Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities.

  2001cited by this paper
• Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II

  2001cited by this paper
• Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.

  2001cited by this paper
• Cyclooxygenase Inhibitors Regulate the Expression of a TGF-β Superfamily Member That Has Proapoptotic and Antitumorigenic Activities

  2001cited by this paper
• Breast cancer and NSAID use: a meta-analysis

  2001cited by this paper
• Nested caseÐcontrol study of the effects of non- steroidal anti-inflammatory drugs on breast cancer risk and stage

  2000cited by this paper
• 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.

  2000cited by this paper
• Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression.

  2000cited by this paper
• Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.

  2000cited by this paper
• Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.

  2000cited by this paper
• The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

  2000cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• Sulindac inhibits activation of the NF-kappaB pathway.

  1999cited by this paper
• Regulation of matrix metalloproteinase expression in tumor invasion

  1999cited by this paper
• Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.

  1999cited by this paper
• PPAR d Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs

  1999cited by this paper
• Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac

  1999influential reference
• Sulindac Inhibits Activation of the NF-κB Pathway*

  1999cited by this paper
• Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.

  1999cited by this paper
• PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

  1999cited by this paper
• Over-the-counter analgesics and risk of ovarian cancer.

  1998cited by this paper
• Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

  1998cited by this paper
• Mechanism of action of antiinflammatory drugs.

  1998influential reference
• Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone).

  1998cited by this paper
• The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β

  1998cited by this paper
• The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.

  1998cited by this paper
• Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.

  1998cited by this paper
• Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties.

  1998cited by this paper
• Cyclooxygenases 1 and 2.

  1998cited by this paper
• Non‐steroidal anti‐inflammatory drugs and prostate cancer progression

  1998cited by this paper
• Mutations of the Apc gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats.

  1998cited by this paper
• Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors.

  1998cited by this paper
• Isoenzyme-specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6.

  1997cited by this paper
• Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.

  1997cited by this paper
• Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs*

  1997cited by this paper
• Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.

  1997cited by this paper
• Sulfone metabolite of sulindac inhibits mammary carcinogenesis.

  1997cited by this paper
• Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration.

  1997cited by this paper
• Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.

  1997cited by this paper
• Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.

  1997cited by this paper

• Association between flurbiprofen axetil use and operative complications occurring following colorectal surgery.

  2025cites this paper
• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Effects of albumin-bound paclitaxel combined with Sophora subprostrate polysaccharide on inflammatory factors and immune function in breast cancer rats

  2025cites this paper
• TRIM32 promotes tumor immune evasion and impedes Anti–PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer

  2025cites this paper
• Rheumatoid arthritis and risk of colorectal cancer: a nationwide cohort study.

  2025cites this paper
• Exploring the antineoplastic potential of novel NSAID derivatives in combatting mammary tumorigenesis: a comprehensive review

  2025cites this paper
• Old and New Analgesic Acetaminophen: Pharmacological Mechanisms Compared with Non-Steroidal Anti-Inflammatory Drugs

  2025cites this paper
• Antitumor efficacy of intermittent low‐dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche

  2025cites this paper
• Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway

  2025cites this paper
• A comparative study of the use of indomethacin with doxorubicin and their pharmacological effects on the growth and reproduction of breast cancer cells (AMJ13) in vitro study

  2025cites this paper
• Causal relationship between anti-inflammatory drugs and cancer: a pan-cancer study with Mendelian randomization

  2024cites this paper
• Induction of mitochondrial toxicity by non-steroidal anti-inflammatory drugs (NSAIDs): The ultimate trade-off governing the therapeutic merits and demerits of these wonder drugs.

  2024cites this paper
• Lung cancer, comorbidities, and medication: the infernal trio

  2024cites this paper
• Effect of Nonsteroidal Anti-inflammatory Drug (NSAID) in Disease Relapse, Progression, and Development of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• High-throughput screening identifies ibuprofen as a small extracellular vesicle PD-L1 inhibitor for synergistic cancer immunotherapy.

  2024cites this paper
• Hepatic Epithelioid Hemangioendothelioma: A Case Report of an Extremely Rare Tumor

  2024cites this paper
• Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update.

  2024cites this paper
• Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription.

  2024cites this paper
• The Past and Future of Inflammation as a Target to Cancer Prevention.

  2024cites this paper
• Deciphering NF-kappaB pathways in smoking-related lung carcinogenesis

  2024cites this paper
• Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies

  2024cites this paper
• A Contemporary Review on the Critical Role of Nonsteroidal Anti-inflammatory Agents in Colorectal Cancer Therapy.

  2024cites this paper
• Novel sulindac derivatives for colorectal cancer chemoprevention that target cGMP phosphodiesterases to suppress Wnt/β-catenin transcriptional activity

  2023cites this paper
• Cyclooxygenase and Cancer: Fundamental Molecular Investigations

  2023cites this paper
• Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer

  2023cites this paper
• Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines

  2023cites this paper
• Synthesis, characterization and biochemical study of novel ester prodrugs containing aspirin and ibuprofen

  2023influential citation
• Diclofenac exhibits cytotoxic activity associated with metabolic alterations and p53 induction in ESCC cell lines and decreases ESCC tumor burden in vivo.

  2023cites this paper
• Wnt/β-Catenin Signaling Pathway in the Development and Progression of Colorectal Cancer

  2023cites this paper
• Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review

  2023cites this paper
• Prescribing Pattern of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Middle East Region: A Critical Review.

  2023cites this paper
• Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Breast Cancer: Evidence from a General Female Population and a Mammographic Screening Cohort in Sweden

  2023cites this paper
• Combination of naproxen and a chemically‐stable eicosapentaenoic acid analog provide additive tumor protection in Pirc rats

  2023cites this paper
• Honokiol, an inducer of sirtuin‐3, protects against non‐steroidal anti‐inflammatory drug‐induced gastric mucosal mitochondrial pathology, apoptosis and inflammatory tissue injury

  2023cites this paper
• Theoretical basis validation and oxidative stress markers for cancer prevention clinical trials of aspirin

  2023cites this paper
• Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.

  2022cites this paper
• A Novel Sulindac Derivative Protects against Oxidative Damage by a Cyclooxygenase-Independent Mechanism

  2022cites this paper
• Nonsteroidal Anti-Inflammatory Drugs as PPARγ Agonists Can Induce PRODH/POX-Dependent Apoptosis in Breast Cancer Cells: New Alternative Pathway in NSAID-Induced Apoptosis

  2022cites this paper
• Cancer on fire: role of inflammation in prevention and treatment

  2022cites this paper
• The Effect of Acetylsalicylic Acid (ASA) on the Mechanical Properties of Breast Cancer Epithelial Cells.

  2022cites this paper
• COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of Type I tumor infiltrating lymphocytes.

  2022cites this paper
• NSAIDs Induce Proline Dehydrogenase/Proline Oxidase-Dependent and Independent Apoptosis in MCF7 Breast Cancer Cells

  2022cites this paper
• Blocking the Wnt/β-catenin signaling pathway to treat colorectal cancer: Strategies to improve current therapies (Review)

  2022cites this paper
• Plasma exosomes in obesity hypoventilation syndrome patients drive lung cancer cell malignant properties: Effect of long-term adherent CPAP treatment.

  2022cites this paper
• Aspirin inhibits the growth of hypertrophic scar in rabbit ears via regulating Wnt/β-catenin signal pathway.

  2022cites this paper
• Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases

  2022cites this paper
• Heart Failure

  2022cites this paper
• Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival

  2022cites this paper
• Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer

  2022cites this paper
• Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies

  2022cites this paper
• Diclofenac: A Nonsteroidal Anti-Inflammatory Drug Inducing Cancer Cell Death by Inhibiting Microtubule Polymerization and Autophagy Flux

  2022influential citation
• Activation of the transcription factor NRF2 mediates the anti-inflammatory properties of a subset of over-the-counter and prescription NSAIDs.

  2022cites this paper
• DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis

  2022cites this paper
• Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention

  2021cites this paper
• Modulating Properties of Piroxicam, Meloxicam and Oxicam Analogues against Macrophage-Associated Chemokines in Colorectal Cancer

  2021cites this paper
• NSAIDs: Old Acquaintance in the Pipeline for Cancer Treatment and Prevention─Structural Modulation, Mechanisms of Action, and Bright Future.

  2021cites this paper
• Perioperative NSAIDs and Long-Term Outcomes After cancer Surgery: a Systematic Review and Meta-analysis

  2021cites this paper
• From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review

  2021cites this paper
• Design, Synthesis, and Biological Evaluation of Novel Triazolothiadiazoles Derived From NSAIDs as Anticancer Agents.

  2021cites this paper
• Rare-earth complexes with anti-inflammatory drug sulindac: Synthesis, characterization, spectroscopic and in vitro biological studies

  2021cites this paper
• Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential

  2021cites this paper
• Ultrafiltration-Based extraction of Ibuprofen from human plasma samples and HPLC analysis: developing an innovative bioanalytical analysis method

  2021cites this paper
• Facing Cell Autophagy in Gastric Cancer – What Do We Know so Far?

  2021cites this paper
• Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin

  2021cites this paper
• Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis

  2021cites this paper
• Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review

  2021cites this paper
• Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database.

  2021cites this paper
• Hyaluronic acid (HA)-coated naproxen-nanoparticles selectively target breast cancer stem cells through COX-independent pathways.

  2021cites this paper
• Gold-Platinum Core-Shell Nanoparticles with Thiolated Polyaniline and Multi-Walled Carbon Nanotubes for the Simultaneous Voltammetric Determination of Six Drug Molecules

  2021cites this paper
• Exploring the therapeutic promise of targeting Rho kinase in rheumatoid arthritis

  2021cites this paper
• Fisetin suppresses 1,2-dimethylhydrazine-induced colon tumorigenesis in Wistar rats via enhancing the apoptotic signaling pathway

  2020cites this paper
• Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity

  2020cites this paper
• Mechanistic studies of in vitro anti-proliferative and anti-inflammatory activities of the Zn(ii)-NSAID complexes of 1,10-phenanthroline-5,6-dione in MDA-MB-231 cells.

  2020cites this paper
• High platelet-to-lymphocyte ratio predicts improved survival outcome for perioperative NSAID use in patients with rectal cancer

  2020cites this paper
• The road ahead for health and lifespan interventions.

  2020cites this paper
• Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome

  2020cites this paper
• Decoding and targeting the molecular basis of MACC1-driven metastatic spread: lessons from big data mining and clinical-experimental approaches.

  2020cites this paper
• Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica Nanoparticles

  2020cites this paper
• Biology, pathology, and therapeutic targeting of RAS.

  2020cites this paper
• Regulation of Autophagy by Non-Steroidal Anti-Inflammatory Drugs in Cancer

  2020cites this paper
• Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells

  2020cites this paper
• Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.

  2020cites this paper
• Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer

  2020cites this paper
• Lifestyle and Cancer Prevention

  2020cites this paper
• Anti-inflammatory drug nanocrystals: state of art and regulatory perspective.

  2020cites this paper
• HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology.

  2020cites this paper
• Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells

  2020cites this paper
• Recent Advances in Desmoid Tumor Therapy

  2020cites this paper
• Anti-Breast Cancer Activities of Ketoprofen-RGD Conjugate by Targeting Breast Cancer Stem-Like Cells and Parental Cells.

  2020cites this paper
• PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity.

  2020cites this paper
• A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor

  2020cites this paper
• Synthesis, toxicity and antitumor activity of cobalt carbonyl complexes targeting hepatocellular carcinoma.

  2019cites this paper
• The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

  2019cites this paper
• Investigating the Effect of Ibuprofen on DLL1 and NOTCH1 Expression in Gastric Cancer Stem Cells Derived from MKN-45 Cell Line

  2019cites this paper
• Potential interaction of inflammatory hyperemia and hyperphosphatemia in tumorigenesis.

  2019cites this paper
• Growth inhibitory effects of PC-NSAIDs on human breast cancer subtypes in cell culture.

  2019cites this paper
• Nociceptive transient receptor potential canonical 7 (TRPC7) mediates aging‐associated tumorigenesis induced by ultraviolet B

  2019cites this paper
• Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs

  2019cites this paper
• Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress

  2019cites this paper
• Population‐based case‐control study: chemoprotection of colorectal cancer with non‐aspirin nonsteroidal anti‐inflammatory drugs and other drugs for pain control

  2019cites this paper